NEO - NeoGenomics Inc (NEO) Q4 2023 Earnings Call Transcript
2024-02-20 19:20:21 ET
NeoGenomics, Inc (NEO)
Q4 2023 Results Conference Call
February 20, 2024 04:30 PM ET
Company Participants
Kendra Sweeney - VP, IR
Chris Smith - CEO
Jeff Sherman - CFO
Vishal Sikri - President, Advanced Diagnostics
Warren Stone - President, Clinical Services
Melody Harris - President of Enterprise Operations
Ali Olivo - General Counsel and Head of Business Development
Conference Call Participants
Alex Nowak - Craig-Hallum
David Westenberg - Piper Sandler
Puneet Souda - Leerink Partners
Matt Sykes - Goldman Sachs
Andrew Brackmann - William Blair
Mark Massaro - BTIG
Mike Matson - Needham & Company
Mason Carrico - Stephens Inc.
Andrew Cooper - Raymond James
John Kim - Bank of America
Tejas Savant - Morgan Stanley
Dan Brennan - TD Cowen
Presentation
Operator
Welcome to the NeoGenomics Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note, this call is being recorded, and an audio replay will be available on the company's website.
Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.
Kendra Sweeney
Thank you, John. Good afternoon, everyone, and welcome to the NeoGenomics fourth quarter and full year 2023 financial results call.
With me today to discuss the results are Chris Smith, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A including Vishal Sikri, President of Advanced Diagnostics; Warren Stone, President of Clinical Services; and Melody Harris, President of Enterprise Operations; and Ali Olivo, General Councel and Head of Business Development.
This call is being simultaneously webcast. We will be referring to a slide presentation that has been posted to the Investors tab on our website at ir.neogenomics.com.
Starting on Slide 2, during this call, we'll be making forward-looking statements regarding our anticipated future performance. We caution you that such statements reflect our best judgment based on factors currently known to us, and that actual events, or results could differ materially. Please refer to our most recent forms 10-K, 10-Q, and 8-K we filed with the SEC, to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements.
The forward-looking statements made during this call speak only as of the original date of the call, and we undertake no obligation to update or revise any of these statements. During this call, in order to provide greater transparency regarding our operating performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results....
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript